642 related articles for article (PubMed ID: 18809449)
1. Adverse event reports following yellow fever vaccination.
Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
[TBL] [Abstract][Full Text] [Related]
2. Adverse event reports following yellow fever vaccination, 2007-13.
Lindsey NP; Rabe IB; Miller ER; Fischer M; Staples JE
J Travel Med; 2016 May; 23(5):. PubMed ID: 27378369
[TBL] [Abstract][Full Text] [Related]
3. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
4. Yellow fever vaccination: how much is enough?
Massad E; Coutinho FA; Burattini MN; Lopez LF; Struchiner CJ
Vaccine; 2005 Jun; 23(30):3908-14. PubMed ID: 15917112
[TBL] [Abstract][Full Text] [Related]
5. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events.
Khromava AY; Eidex RB; Weld LH; Kohl KS; Bradshaw RD; Chen RT; Cetron MS;
Vaccine; 2005 May; 23(25):3256-63. PubMed ID: 15837230
[TBL] [Abstract][Full Text] [Related]
6. Prevention of yellow fever in persons traveling to the tropics.
Monath TP; Cetron MS
Clin Infect Dis; 2002 May; 34(10):1369-78. PubMed ID: 11981733
[TBL] [Abstract][Full Text] [Related]
7. Review of the risks and benefits of yellow fever vaccination including some new analyses.
Monath TP
Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
[TBL] [Abstract][Full Text] [Related]
8. [Yellow fever vaccination: update on rare and severe adverse effects].
Receveur MC; Bruyand M; Pistone T; Malvy D
Med Mal Infect; 2009 Apr; 39(4):234-41. PubMed ID: 19167852
[TBL] [Abstract][Full Text] [Related]
9. Yellow fever vaccination: some thoughts on how much is enough [Vaccine 23 (2005) 3908-3914].
Martins RM; Galler R; Freire MS; Camacho LA; de Lourdes S Maia M; Homma A
Vaccine; 2007 Jan; 25(1):10-1. PubMed ID: 16448728
[TBL] [Abstract][Full Text] [Related]
10. Safety of the yellow Fever vaccine: a retrospective study.
Nordin JD; Parker ED; Vazquez-Benitez G; Kharbanda EO; Naleway A; Marcy SM; Molitor B; Kuckler L; Baggs J
J Travel Med; 2013; 20(6):368-73. PubMed ID: 24118538
[TBL] [Abstract][Full Text] [Related]
11. Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007.
Niu MT; Ball R; Woo EJ; Burwen DR; Knippen M; Braun MM;
Vaccine; 2009 Jan; 27(2):290-7. PubMed ID: 18992783
[TBL] [Abstract][Full Text] [Related]
12. Age-related risk of adverse events following yellow fever vaccination in Australia.
Lawrence GL; Burgess MA; Kass RB
Commun Dis Intell Q Rep; 2004; 28(2):244-8. PubMed ID: 15460963
[TBL] [Abstract][Full Text] [Related]
13. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).
Sever JL; Brenner AI; Gale AD; Lyle JM; Moulton LH; Ward BJ; West DJ
Pharmacoepidemiol Drug Saf; 2004 Dec; 13(12):825-40. PubMed ID: 15386719
[TBL] [Abstract][Full Text] [Related]
14. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast.
Fitzner J; Coulibaly D; Kouadio DE; Yavo JC; Loukou YG; Koudou PO; Coulombier D
Vaccine; 2004 Nov; 23(2):156-62. PubMed ID: 15531032
[TBL] [Abstract][Full Text] [Related]
15. Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):989-93. PubMed ID: 12455906
[TBL] [Abstract][Full Text] [Related]
16. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010.
Vellozzi C; Broder KR; Haber P; Guh A; Nguyen M; Cano M; Lewis P; McNeil MM; Bryant M; Singleton J; Martin D; DeStefano F
Vaccine; 2010 Oct; 28(45):7248-55. PubMed ID: 20850534
[TBL] [Abstract][Full Text] [Related]
17. Transfusion-related transmission of yellow fever vaccine virus--California, 2009.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Jan; 59(2):34-7. PubMed ID: 20094025
[TBL] [Abstract][Full Text] [Related]
18. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Staples JE; Gershman M; Fischer M;
MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
[TBL] [Abstract][Full Text] [Related]
19. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.
Kitchener S
Vaccine; 2004 Jun; 22(17-18):2103-5. PubMed ID: 15149765
[TBL] [Abstract][Full Text] [Related]
20. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.
McMahon AW; Iskander J; Haber P; Chang S; Woo EJ; Braun MM; Ball R
Pediatrics; 2005 Feb; 115(2):453-60. PubMed ID: 15687455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
